Drugs / L-methylfolate
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01853280 | May 2014 → Feb 2017 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06218030 | Oct 2024 → Apr 2026 overdue | generalized anxiety disorder | Queen's University | Recruiting | No outcome recorded |
| Phase 4 | NCT04782037 | Oct 2020 → Jul 2022 | acute diarrhea | King Edward Medical University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT05807711 Comparator | Apr 2023 → May 2024 | end stage renal failure, renal hypertension | Alexandria University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02223299 Background | Nov 2015 | major depressive disorder | John D. Dingell VA Medical Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-methylfolate | “Patients will be assigned to take one tablet daily containing L-methylfolate and methylcobalamine.” NCT05807711 ↗ |
| Known as | deplin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02223299 ↗ |
| Route | Oral | “Oral administration of L-methylfolate 15 mg per day for 8 weeks.” NCT06218030 ↗ |